HPLC-UV测定大鼠血浆中氧化槐定碱含量及其药代动力学研究

建立测定大鼠血浆中氧化槐定碱的体内分析方法,并考察其药代动力学参数。血浆样品以甲醇溶液沉淀,采用ZORBAX XDB-C18(150 mm×4.6 mm,4.0μm)色谱柱分离,流动相为乙腈-磷酸缓冲溶液(0.01 mol/L KH2PO4,H3PO4调p H 3.30)=4∶96(V/V),检测波长210 nm。血浆中氧化槐定碱在2.50~500.00μg/m L内线性较好(r=0.9971),提取回收率为77.3%~89.9%,日内、日间精密度RSD均小于10%。大鼠静脉注射50mg/kg和100 mg/kg氧化槐定碱后,其消除半衰期t1/2分别为(37.24±9.27)和(34.25±8.82)min,AUC分别为(1998.76±178.35)和(5130.62±1450.86)mg/L/min,Cmax分别为(89.53±10.47)和(247.35±112.02)mg/L。本文建立的方法简便、经济,可用于氧化槐定碱体内药代动力学分析。     

不同水温下氟甲砜霉素在斑点叉尾鮰体内的药代动力学研究

研究不同水温(18℃和28℃)条件下,单剂量(10mg/kgb·w)强饲氟甲砜霉素,在斑点叉尾鮰(Ictaluruspunc-tatus)体内药代动力学特征.采用高效液相色谱紫外检测法可以同时检测血浆中氟甲砜霉素及其代谢物氟甲砜霉素的浓度.用3p97药代动力学软件处理药时数据.结果表明:在不同水温条件下氟甲砜霉素在斑点叉尾鮰体内的药时数据均符合一室开放式模型.药时规律符合理论方程C血浆=71921(e-0.036t-e-0.18t)和C血浆=91061(e-0.081t-e-0.301t).18℃和28℃的条件下,主要药代动力学参数:吸收半衰期T1/2ka分别为31845h和21301h,消除半衰期T1/2ke分别为191118h和81519h,达峰时间Tpeak分别为111136h和51953h,最大血药浓度Cmax分别为41074μg/mL和41226μg/mL,曲线下面积AUC分别为1741547(μg/mL)/h和811279(μg/mL)/h,平均驻留时间MRT分别为271581h和121290h,相对表观分布容积V/F(c)分别为11580L/kg和115121L/kg.采用氟甲砜霉素防治斑点叉尾鮰细菌性疾病,建议在18℃左右口服10mg/kg体重剂量的氟甲砜霉素,2d给药1次;在28℃左右口服10mg/kg体重剂量的氟甲砜霉素,1d给药1次.试验过程中在斑点叉尾鮰血浆样品中未检测到氟甲砜霉素的主要代谢物氟甲砜霉素胺.       

重组人血管内皮抑素在Beagle犬体内的药代动力学研究

研究重组人血管内皮抑素(rhEndostatin)静脉注射后在Beagle犬体内的药代动力学过程,为临床应用提供药代动力学数据。用酶联免疫吸附试验(ELISA)竞争法检测Beagle犬静脉注射rhEndostatin后不同时间的血药浓度,并将血药浓度-时间数据经计算机拟合,计算出相应参数。rhEndostatin静脉注射Beagle犬后,药物的分布半衰期平均为(0.34±0.04)h,消除半衰期为(16.5±1.6)h。血药浓度-时间曲线下面积(AUC)与剂量呈正相关,相关系数为0.999 9。血浆清除率(CLs)均值为(0.123±0.006)l/h,高、中、低剂量CLs基本相同。rhEndostatin在Beagle犬体内的药代动学过程基本符合线性药动学特征,血药浓度-时间曲线符合二房室模型。rhEndostatin在Beagle犬体内药代动力学过程的研究对其进一步开发具有指导价值。     

RP-HPLC法测定阿托伐他汀在新西兰兔体内的药代动力学

目的:研究阿托伐他汀片在新西兰兔体内的药代动力学.方法:18只成年健康雄性新西兰兔.随机分为正常对照组、10mg/kg·d阿托伐他汀片组与15 mg/kg·d阿托伐他汀片组,每组6只,采用RP-HPLC法测定血药浓度,计算药代动力学参数.结果:10mg/kg·d组与15 mg/kg·d组的主要药代动力学参数分别为:AUC0～t/μ g·L-1·h为(619.58±215.45)与(1138.34±422.32)、AUC0～∞/μ g·L-1·h为(655.68±242.83)与(1216.57±353.64)、Cmax/μ g·L-1为(455.81±168.52)和(896.53±168.5.8)、MRT0～t/h为(3.68±0.75)与(5.73±0.56)、MRT0～∞/h为(3.83±0.91)与(5.25±0.48)、Tmax/h为(2.51±0.82)与(3.68±0.33)、T1/2/h为(4.22±0.55)与(9.51±0.67).结论:RP-HPLC法适用于阿托伐他汀片动物药代动力学的研究.     

雷诺嗪缓释片在比格犬体内的药代动力学

目的:研究雷诺嗪缓释片在比格犬体内的药物代谢动力学,并与参照制剂比较,为其是否具有缓释特征提供依据。方法:首先建立血浆中雷诺嗪浓度的液相色谱-串联质谱联用检测方法,并考察方法的专属性、准确度、日内日间精密度、回收率、线性范围等。采用随机对照试验设计,将12只比格犬随机分为A、B组,每组6只,分别服用1片雷诺嗪缓释片(500 mg/片)和1片参比制剂雷诺嗪片(500 mg/片),均于给药前和给药后不同时间点采集血样,用已建立的液质联用方法检测血样中雷诺嗪的血药浓度,计算2组比格犬的药代动力学参数。结果:受试组和参照组半衰期t1/2分别为13.3±8.3和2.36±0.92 h,峰浓度Cmax分别为923.9±340.5和3205±1314 ng/mL,达峰时间Tmax分别为1.6±0.38和0.88±0.14 h,曲线下面积AUC0~∞分别为6252.1±2860.3和9916±4305(ng·h)/mL,清除率Cl分别为11.3±9.8和6.39±3.95 L/(kg·h)。受试制剂雷诺嗪缓释片和参比制剂雷诺嗪片的药代特征和血药浓度-时间变化趋势明显不同,受试组血药浓度缓慢上升和下降,峰值较低;而参照组血药浓度峰值显著高于受试组,有明显的突释效应。结论:液质联用检测方法准确可靠,适合体内药代动力学研究;与参比制剂雷诺嗪片相比,受试制剂雷诺嗪缓释片符合缓释片的基本药代动力学特点。     

盐酸氯苯胍在美国红鱼体内的药代动力学和残留消除规律研究

在水温(28±2)℃、盐度28条件下,盐酸氯苯胍(robenidine hydrochloride,ROBH)按30 mg/kg的剂量口灌实验鱼,用HPLC-MS/MS法研究盐酸氯苯胍在美国红鱼体内的药代动力学和残留消除规律。结果显示,单剂量口灌给药后,美国红鱼血浆中ROBH的药时数据符合一级吸收二室模型,药物在血浆中的达峰时间(tp)、血药浓度峰值(Cmax)、药时曲线下面积(AUC_(0-∞))和消除半衰期(t_(1/2β))分别为2.39 h、958.78μg/L、33 247.57μg/(L·h)和19.24 h;ROBH在肌肉、肝脏和肾脏的Cmax分别为156.72μg/kg、227.68μg/kg和553.44μg/kg,tp分别为2.0 h、1.5 h、2.0 h;AUC_(0-∞)分别4 664.04μg/(kg·h)、4 897.74μg/(kg·h)、17 228.19μg/(kg·h);t_(1/2β)分别为19.68 h、24.33 h和22.81 h。按30 mg/kg剂量连续5 d口灌给药后,美国红鱼肌肉、肝脏、肾脏中的药物消除半衰期(t1/2):24.46 h、35.39 h、39.60 h和33.94 h。若以10μg/kg为最高残留限量,肌肉作为食用靶组织,在本试验条件下,建议休药期不少于7 d。     

氟苯尼考及氟苯尼考胺在克氏原螯虾体内药物代谢动力学

研究不同给药方式下,氟苯尼考及其代谢产物氟苯尼考胺在克氏原螯虾体内的药动学特征。在水温为(21±1)℃条件下,分别给予20 mg/kg体重单剂量血窦注射或50 mg/kg体重单剂量口灌给药,并于0.083、0.25、0.5、1、2、3、4、6、8、12、18、24和36h时间点采集血淋巴,运用反相色谱法检测血淋巴中氟苯尼考及氟苯尼考胺的浓度,采用3p97软件的非房室模型统计矩方法分析药时数据。结果表明:血窦给药后,氟苯尼考的消除半衰期(t1/2)、表观分布容积[Vd(ss)]、总体清除率(CL)分别为8.26h、14.43 L/kg、1.21 L/kg.h,氟苯尼考胺消除半衰期和代谢率(MR)分别为20.28h、9.3%;口灌给药后,氟苯尼考达峰浓度(Cmax)、达峰时间(Tmax)、消除半衰期、生物利用度(F)分别为2.49 mg/kg、1.0h、10.01h、21.6%,氟苯尼考胺的消除半衰期和代谢率分别为16.0h、37.5%。氟苯尼考在克氏原螯虾体内的消除比氟苯尼考胺快,并能广泛地分布于身体各组织中;氟苯尼考在胃肠中吸收迅速,但其生物利用度不高,代谢率低。     

烟酸诺氟沙星在松浦镜鲤体内的药动学特征

结合单纯聚集法和二步法,应用高效液相色谱(HPLC)技术研究了分别以10、30、60 mg/kg剂量对松浦镜鲤(Cyprinus carpio specularis)口灌烟酸诺氟沙星后,药物在实验鱼血浆中的药动学特征。3种给药剂量下,诺氟沙星在松浦镜鲤血浆中的血药浓度和时间关系均可用一级吸收二室开放模型进行描述,吸收半衰期(t1/2ka)分别为0.165、0.061、0.043 h,消除半衰期(t1/2β)分别为18.282、29.969、42.051 h,达峰时间(Tmax)分别为0.333、0.327、0.302 h,达峰浓度(Cmax)分别为4.780、6.247、12.689 mg/L,药时曲线下面积(AUC)分别为32.698、53.015、174.998 mg·h/L,表观分布容积(Vd)分别为1.044、4.347、4.561 L/kg。说明随着给药剂量的增加,诺氟沙星的吸收和消除速率均加快,给药剂量对药动学特征有显著影响。     

液相色谱-串联质谱法同时测定大鼠血浆中阿霉素和塞来昔布

目的:建立同时测定大鼠血浆中阿霉素和塞来昔布的液相色谱-串联质谱(LC/MS/MS)方法,研究这两种药物联合应用的药代动力学.方法:大鼠尾静脉注射阿霉素和塞来昔布,眼眶取血并抗凝,离心分离血浆,采用乙酸乙酯提取血浆中的阿霉素和塞来昔布,N2吹干乙酸乙酯,残留物用50μL甲醇溶解,取20μL用于LC/MS/MS分析.结果:用LC/MS/MS法检测大鼠血浆中阿霉素和塞来昔布的线性范围为1-800ng/mL,日内、日间精密度(RSD)均小于15%,检测血浆低、中、高三个浓度(8、50、500ng/mL)阿霉素的回收率分别为101.2%、95.1%和91.4%,检测血浆低、中、高三个浓度(8、50、500ng/mL)塞来昔布的回收率分别为105.6%、106.8%和93.7%.大鼠尾静脉注射5.8mg/kg阿霉素和3.8mg/kg塞来昔布的半衰期分别为2.3 h和3.6h,曲线下面积分别为670 ng·h·mL-1和1480ng·h·mL-1.结论:建立的方法灵敏、准确、快速,适甩于阿霉素和塞来昔布的药代动力学研究.     

阿魏酸及其不同配伍药代动力学比较研究

本文主要探讨阿魏酸及其不同配伍给药在大鼠体内的代谢动力学规律。将32只SD大鼠,分为阿魏酸组50 mg/kg、阿魏酸+川芎嗪(50 mg/kg+30 mg/kg)组、阿魏酸+延胡索乙素(50 mg/kg+20 mg/kg)组、阿魏酸+川芎嗪+延胡索乙素(50 mg/kg+30 mg/kg+20 mg/kg)组,分别灌胃给药,采用高效液相色谱法测定各组大鼠血浆中阿魏酸的浓度,DAS2.0程序计算药代动力学参数。结果表明:川芎嗪、延胡索乙素均可延长阿魏酸在大鼠体内的作用时间,增加阿魏酸在大鼠体内的吸收。     

Quantification of a novel natural antioxidant (UP302) in rat plasma using ultra-high performance liquid chromatography-tandem mass spectrometry

UP302 is a novel natural antioxidant isolated from Dianella ensifolia (Liliaceae). In the investigation, a specific and sensitive ultra-high performance liquid chromatography-tandem mass spectrometry for quantitative determination of UP302 in rat plasma was developed and validated. UP302 and the internal standard daidzein were extracted from 100 μL aliquots of rat plasma using methanol. Detection of UP302 and IS was done by tandem mass spectrometry, operating in negative ion and selected reaction monitoring acquisition mode. The precursor-product ion transitions monitored for UP302 and daidzein were m/z 301.1→135.2 and 252.9→132.0, respectively. The linearity of the method was observed within the concentration range of 5-2000 ng/mL. Intra- and inter-day assay variations were less than 15%, and the accuracy values were between 99.2% and 107.3%. The method was successfully applied to stability investigation of UP302 incubated in rat plasma at 37°C and measurement of UP302 in plasma after intravenous administration of UP302 to rats at a single dose of 5 mg/kg. Incubation stability revealed that within first one hour, UP302 was rapidly declined approximately 35% and remained stable after 4 h. Pharmacokinetic values of half-life, volume of distribution, systemic clearance and mean residence time were 0.87 ± 0.58 h, 6.90 ± 3.35 L/kg, 5.89 ± 1.21 L/h kg and 0.34 ± 0.13 h, respectively.     

Plasma clearance and half-life of prostaglandin F2alpha: a comparison between mares and heifers

Horses are about five times more sensitive to the luteolytic effect of prostaglandin F2alpha (PGF) than cattle, as indicated by a recommended clinical dose of 5 mg in horses and 25 mg in cattle. Novel evaluations of the PGF plasma disappearance curves were made in mares and in heifers, and the two species were compared. Mares and heifers (n = 5) of similar body weight were injected (Min 0) intravenously with PGF (5 mg per animal). Blood was sampled every 10 sec until Min 3, every 30 sec until Min 5, every 10 min until Min 60, and every 30 min until Min 240. The mean PGF concentration was greater (P < 0.05) in mares than in heifers at Min 1 through Min 60 and at Mins 180 and 240. The mean time to maximum PGF concentration was not different between mares (42.0 ± 8.6 sec) and heifers (35.0 ± 2.9 sec). The apparent plasma clearance, distribution half-life, elimination half-life, and maximum plasma PGF concentration were 3.3 ± 0.5 L h(-1) kg(-1), 94.2 ± 15.9 sec, 25.9 ± 5.0 min, and 249.1 ± 36.8 ng/ml, respectively, in mares and 15.4 ± 2.3 L h(-1) kg(-1), 29.2 ± 3.9 sec, 9.0 ± 0.9 min, and 51.4 ± 22.6 ng/ml, respectively, in heifers. Plasma clearance was about five times less (P < 0.0005), maximum plasma PGF concentration was five times greater (P < 0.002), and the distribution half-life and elimination half-life were about three times longer (P < 0.005) in mares than in heifers. The fivefold greater plasma clearance of PGF in heifers than in mares corresponds to the recommended fivefold greater clinical dose of PGF in cattle and supported the hypothesis that the metabolic clearance of PGF is slower in mares than heifers.     

Reduction of the sevoflurane minimum alveolar concentration induced by methadone, tramadol, butorphanol and morphine in rats

This study aimed to estimate the reduction in the minimum alveolar concentration (MAC) of sevoflurane induced by low and high doses of methadone (5 and 10 mg/kg), tramadol (25 and 50 mg/kg), butorphanol (5 and 10 mg/kg) or morphine (5 and 10 mg/kg) in the rat. A control group received normal saline. Sixty-three adult male Sprague-Dawley rats were anaesthetized with sevoflurane (n = 7 per group). Sevoflurane MAC was then determined before and after intraperitoneal administration of the opioids or saline. The duration of the sevoflurane MAC reduction and basic cardiovascular and respiratory measurements were also recorded. The baseline MAC was 2.5 (0.3) vol%. Methadone, tramadol and morphine reduced the sevoflurane MAC (low dose: 31 ± 10, 38 ± 15 and 30 ± 13% respectively; high dose: 100 ± 0, 83 ± 17 and 77 ± 25%, respectively) in a dose-dependent manner. The low and high doses of butorphanol reduced the sevoflurane MAC to a similar extent (33 ± 7 and 31 ± 4%, low and high doses, respectively). Two rats developed apnoea following administration of high-dose butorphanol and methadone. These anaesthetic-sparing effects are clinically relevant and may reduce the adverse effects associated with higher doses of inhalational anaesthetics.     

强力霉素在斑点叉尾(鲴)体内药物动力学及残留消除规律研究

研究利用高效液相色谱法研究了强力霉素在斑点叉尾 (Ictalurus punctatus)体内的药物动力学与消除规律, 有助于制定合理用药方案和休药期, 为水产品质量安全提供理论依据。(1)单次口服剂量 20 mg/kg 强力霉素在斑点叉尾 体内的药时数据符合二室开放式模型。药-时曲线呈明显双峰现象: 第一次达峰时, 强力霉素在肾、血和肌肉中浓度迅速上升, 达峰时间 Tmax (1)出现在 30min, 强力霉素在肝脏中浓度上升缓慢, 出现在 1h; 肝、肾、血和肌肉第二次达峰的时间 Tmax (2)出现在 8h, 第二次达峰浓度 Cmax(2)大于第一次的浓度Cmax (1)。 药-时曲线下面积(AUC): 肾、肝、血和肌肉分别为 63.242、1282.077、142.379、62.348 μg·h /mL。消除半衰期[T1/2b]: 肾、肝、血和肌肉分别为 40.668、48.767、36.527、31.091h, 平均滞留时间(MRT): 肾、肝、血和肌肉分别为 46.585、56.989、48.859、42.428h; (2)连续口服剂量 20 mg/kg 的强力霉素 5d, 停药后强力霉素在斑点叉尾 肝脏中浓度最高, 肌肉+皮中浓度最低。在不同组织中强力霉素的消除速率不同(P<0.05), 药物消除速度由高到低依次为肌肉+皮、肾脏、肝脏。若以肝脏为靶组织, 最高残留限量 300 μg/kg,休药期不低于 30d; 若以可食组织肌肉+皮为靶组织, 最高残留限量 300 μg/kg, 休药期不低于 19d。     

草毡寒冻雏形土CO2释放特征

研究了植物生长季节海北高寒草甸生态系统高寒嵩草草甸覆被下草毡寒冻雏形土的 CO2 释放速率。其结果表明 :CO2 释放速率有明显的日变化和季节动态。日最大排放速率多出现在 1 4 :0 0～ 1 6:0 0时 ,最小排放速率在 6:0 0～ 8:0 0时。植物生长季日最大振幅为 797.75mg/m2·h,最小振幅 1 97.33mg/m2·h。CO2 排放白天大于夜晚。不同物候期 CO2 释放速率不同 ,其顺序为草盛期 >枯黄期 >返青期。生长季土壤 CO2 释放速率的范围是 4 41 .72 mg/m2 · h± 1 55.2 9mg/m2· h,最大日均值为 681 .0 6mg/m2 · h( 7月 1 6日 ) ,最低值 1 76.65mg/m2 · h ( 6月 1日 )。退化草地土壤 CO2 释放速率明显低于未退化草地 ,生长季平均日均值低 1 37.4 7mg/m2·h。相关分析表明 :土壤 CO2 排放速率与气温、地表温度、土壤5cm、1 0 cm、1 5cm、2 0 cm、30 cm地温均呈显著和极显著相关关系。温度是影响土壤 CO2 释放速率的主要因子。     

Pharmacokinetics Study of Recombinant Hirudin in the Plasma of Rats Using Chromogenic Substrate,ELISA, and Radioisotope Assays

Aim

To compare the analytical methods used to study the pharmacokinetics of recombinant hirudin in the plasma of rats that had been injected with ¹²⁵I-recombinant hirudin.

Methods

2.0 mg/kg ¹²⁵I-recombinant hirudin were injected intravenously into rats. The recombinant hirudins in the plasma was analyzed by chromogenic substrate assay, enzyme-linked immunosorbent assay (ELISA), total radioisotope assay (RA) and trichloroacetic acid pre-treated total radioisotope assay (TCA-RA).

Results

The chromogenic substrate assay standard curve was linear over the concentration range from 3.12 to 40.00 ng/ml for the recombinant hirudin in plasma. The relative standard deviations (RSD) for the intra- and inter-day variation were 5.0 to 6.3% and 11.9 to 12.6%, respectively. The recoveries of recombinant hirudin was 89.8% to 100.7%. The limit of quantification (LOQ) was 3.12 ng/ml. The concentration-time curve of the recombinant hirudin in the plasma could be explained as a two-compartment model. Pharmacokinetic parameters, including the half-life of distribution phase (t_1/2 α), the half-life of elimination phase (t_1/2 β), volume of apparent distribution (Vd), and area under the concentration-time curve from zero to infinite time (AUC_0–t) were 7.59 min, 46.99 min, 0.17 L/kg, and 204.5 mg/L/min, respectively, as determined by chromogenic substrate assay; 6.41 min, 47.28 min, 1.24 L/kg, and 575.18 mg/L/min, respectively, as determined by ELISA; 3.69 min, 701.90 min, 0.04 L/kg, and 4189 mg/L/min, respectively as determined by RA; and 4.57 min, 724.9 min, 0.09 L/kg, and 2329 mg/L/min, respectively, as determined by TCA-RA.

Conclusions

The chromogenic substrate assay on the concentration dynamics of the recombinant hirudin in the plasma is a specific, sensitive, and accurate analytical method for pharmacokinetic studies. Moreover, the pharmacokinetic parameters determined by the chromogenic substrate assay and ELISA are congruent except for AUC.     

草鱼体内双氟沙星药代动力学研究

为研究双氟沙星（Difloxacin,DIF）在草鱼（Ctenopharynodon idellus）体内的药代动力学以及在各组织中的残留量,采用高效液相色谱法测定在15℃水温状态下单次给草鱼灌喂20 mg/kg剂量的双氟沙星后,得出双氟沙星在各组织以及血液中的药时曲线均都符合二室开放性模型,双氟沙星能够在草鱼体内快速吸收,并且血液及各组织中均有分布,双氟沙星在草鱼体内的药物动力学方程为C=5.056e-0.012t+19.041e-0.011t,其中双氟沙星在血液、肌肉、肝脏、肾脏中吸收半衰期（T_1/2α）分别为0.176h、0.562h、4.562h和1.477h,消除半衰期分别为（T_1/2β）69.492h、65.303h、218.412h和163.937h,总体消除率（CL）分别为0.495、11.181、10.789和7.102 L/（h·kg）,药时曲线下面积（AUC）分别为81.550、1277.55、807.470和1432.150 μg/（L·h）。根据相关规定肌肉中双氟沙星最大残留量300 μg/kg为标准,建议休药期26d以上。     

氯胺酮对抑郁大鼠模型抗抑郁作用研究

目的:探讨在抑郁大鼠模型中单次氯胺酮可产生快速持久地抗抑郁作用。方法:实验一:32只Wistar大鼠随机分为四组(n=8),药物干预前1 d大鼠强迫游泳15 min,药物干预当天,分别腹腔注射相同容积的生理盐水(S组)、5 mg/kg氯胺酮(K5组)、10 mg/kg氯胺酮(K10组)、15 mg/kg氯胺酮(K15组)。30 min后记录大鼠运动能力及不动时间。实验二:20只Wistar大鼠随机分为两组(n=10),所有大鼠均经历21天慢性不可预知应激试验。第22天大鼠分别腹腔注射相同容积生理盐水及10 mg/kg氯胺酮,于干预前、干预后1 h、2 h、6 h、1 d、4 d、7 d分别进行敞箱试验,并记录大鼠水平运动及垂直运动得分。结果:与S组相比,K5、K10及K15组大鼠运动能力无明显变化(P>0.05)且强迫游泳不动时间均显著减少(P<0.01);与干预前生理盐水组相比,生理盐水干预后1 h、2 h、6 h、1 d、4 d及7 d组大鼠敞箱试验水平运动及垂直运动均无明显差异(P>0.05);与干预前氯胺酮组相比,生理盐水干预后1 h、2 h、6 h、1 d、4 d及7 d组大鼠敞箱试验水平运动及垂直运动有明显差异(P<0.05)。结论:在抑郁症大鼠模型中氯胺酮可产生快速且持久的抗抑郁作用。     

Artesunate: developmental toxicity and toxicokinetics in monkeys

BACKGROUND: The developmental toxicity, toxicokinetics, and hematological effects of the antimalarial drug, artesunate, were previously studied in rats and rabbits and have now been studied in cynomolgus monkeys. METHODS: Groups of up to 15 pregnant females were dosed on Gestation Days (GD) 20–50 or for 3–7‐day intervals. RESULTS: At 30 mg/kg/day, 6 embryos died between GD30 and GD40. Histologic examination of 3 live embryos (GD26–GD36) revealed a marked reduction in embryonic erythroblasts and cardiomyopathy. At 12 mg/kg/day, 6 embryos died between GD30 and GD45. Four surviving fetuses examined on GD100 had no malformations, but long bone lengths were slightly decreased. At the developmental no‐adverse‐effect‐level (4 mg/kg/day), maternal plasma AUC was 3.68 ng.h/mL for artesunate and 6.93 ng.h/ml for its active metabolite, dihydroartemisinin (DHA). No developmental toxicity occurred with administration of 12 mg/kg/day for 3 or 7 days, GD29–31 or GD27–33 (maternal plasma AUC of 9.84 ng.h/mL artesunate and 16.4 ng.h/mL DHA). Exposures at embryotoxic doses were substantially lower than human therapeutic exposures. However, differences in monkey and human Vss for artesunate (0.5 L/kg vs. 0.18 L/kg) confound relying solely on AUC for assessing human risk. Decreases in reticulocyte count occur at therapeutic doses in humans. Changes to reticulocyte counts at embryotoxic doses in monkeys (≥12 mg/kg/day) were variable and generally minor. CONCLUSIONS: Artesunate was embryolethal at ≥12 mg/kg/day when dosed for at least 12 days at the beginning of organogenesis, but not when dosed for 3 or 7 days, indicating that developmental toxicity of artesunate is dependent upon duration of dosing in cynomologus monkeys. Birth Defects Res (Part B) 83:418–434, 2008. © 2008 Wiley‐Liss, Inc.     

内毒素在大剂量顺铂所致大鼠急性肾损伤过程中的变化及意义

目的利用大剂量顺铂（cisplatin,DDP）所致大鼠急性肾功能衰竭的动物模型,观察外周血内毒素（endotoxin）在大鼠急性肾损伤中的变化及其意义。方法SD大鼠36只,雌雄各半,依体重随机分为DDP用药6h、48h、对照组和生理盐水（NS）用药6h、48h、对照组,每组6只。10mg／kgDDP单次腹腔内注射,等量Ns对照。观察并记录用药后对照组大鼠的毒副反应;用药6、48h各组大鼠无菌条件下心脏穿刺取血、肝素抗凝,检测外周血内毒素含量,同时内眦静脉取血,测定血清尿素氮、肌酐浓度,并进行统计学分析。结果DDP用药后6h,大鼠体重开始明显降低,用药48h后,大鼠腹泻逐渐加重,用药3d后大鼠死亡。DDP用药后6h大鼠血尿素氮、肌酐的含量与对照组比较差异无显著性（P〉0．05）;DDP用药后48h血尿素氮升至（18．71±9．9）mmol／L,明显高于对照组（7．48±0．6）mmol／L（P〈0．05）,同时血肌酐含量亦升至（49．6±14．1）μmol／L,与对照组（27．17±1．7）μmol／L比较差异具有显著性（P〈0．05）。DDP用药后6h所有大鼠外周血内毒素含量都低于0．0218Eu／rrd最低检出限,明显低于NS对照组大鼠（0．3141±0．1477）Eu／ml（P〈0．01）;DDP用药后48h大鼠外周血内毒素的含量增高均超过0．70Eu／ml最高检出限,明显高于NS对照组大鼠（0．1661±0．1198）Eu／ml（P〈0．01）。结论外周血内毒素含量的变化与大剂量顺铂所致大鼠急性肾损伤早期的发病机制无关,但与大鼠肾功能衰竭有关的发生相关。